cjc 1295 mk-677: Frequently asked questions

First, confirm compliance. Inconsistent MK-677 dosing is the most common cause of apparent plateau. If compliance is verified, plateau suggests receptor desensitization (more common with MK-677 than CJC-1295) or hepatic IGF-1 production reaching saturation. The corrective options depend on study goals: (1) Maintain the current dose and accept the plateau as the physiological ceiling for that subject. Further dose escalation yields diminishing returns and higher side effect incidence. (2) Introduce a 7–10 day washout period for MK-677 only (continue CJC-1295 weekly dosing) to allow GHSR-1a receptors to upregulate, then resume MK-677 at the same dose. (3) If the study design permits, increase CJC-1295 to 2mg weekly (if currently at 1mg). GHRH receptor desensitization is rare, and higher CJC-1295 doses often restore IGF-1 elevation even when MK-677 response has plateaued.

Discard the vial immediately. Cloudiness indicates protein aggregation or contamination, both of which render the compound ineffective and potentially unsafe for research use. Aggregation occurs when the peptide structure unfolds and clumps, usually triggered by temperature excursion above 8°C, mechanical shear during reconstitution (shaking instead of gentle rotation), or bacterial contamination. Once aggregation is visible, the damage is irreversible. Re-examine your reconstitution technique: inject bacteriostatic water down the vial wall at a 45-degree angle, never directly onto the pellet, and allow 90–120 seconds for passive dissolution before gentle rotation.